Eagle Pharmaceuticals Company Profile (NASDAQ:EGRX)

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Eagle Pharmaceuticals announced that its Board of Directors has authorized a share repurchase program on Thursday, August 10th 2017, which authorizes the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 13.3% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company's board of directors believes its shares are undervalued.

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced its earnings results on Wednesday, August, 9th. The company reported $0.33 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.51 by $0.18. The company earned $50.10 million during the quarter, compared to analyst estimates of $52.52 million. Eagle Pharmaceuticals had a return on equity of 66.30% and a net margin of 39.32%. Eagle Pharmaceuticals's quarterly revenue was up 22.5% on a year-over-year basis. During the same period last year, the business posted $0.80 EPS. View Eagle Pharmaceuticals' Earnings History.

4 analysts have issued 12 month price objectives for Eagle Pharmaceuticals' shares. Their predictions range from $40.00 to $97.00. On average, they anticipate Eagle Pharmaceuticals' share price to reach $73.25 in the next year. View Analyst Ratings for Eagle Pharmaceuticals.

Here are some recent quotes from research analysts about Eagle Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. " (7/31/2017)
• 2. Mizuho analysts commented, "We remain cautious on 2017 revenue, the exertional heat stroke (EHS) launch, and lower takeout probability: Eagle reported 4Q:16 revs of $81.1M and GAAP EPS of $3.52 vs. FactSet consensus $86.0M and $2.82. Mgmt introduced FY:17 SG&A guidance of $65-$68M and $31-$35M in R&D. Consensus models are in line with these expense ranges, but we think that 2017 revenue expectations (particularly Ryanodex) need to come down based on a slower EHS ramp. Because we now have a better appreciation for the hurdles associated with this launch, we also lowered our probability of takeout to 40%, from 50% previously. On a standalone basis, we think that EGRX is only worth $54/share so the stock already reflects expectations of a takeout, in our view. We reiterate our Underperform rating and $66 PT, which are based on a weighted blend of DCF ($54) and SOTP ($85) valuations." (3/17/2017)

Some companies that are related to Eagle Pharmaceuticals include Repligen Corporation (RGEN), TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Aimmune Therapeutics (AIMT), Assembly Biosciences (ASMB), Rockwell Medical (RMTI), NOVAN INC (NOVN), Check-Cap (CHEK), CorMedix (CRMD), DARA Biosciences (DARA), Macrocure Ltd (MCUR) and Salix Pharmaceuticals (SLXP).

Eagle Pharmaceuticals' management team includes the folowing people:

• Michael Graves, Independent Chairman of the Board
• Scott L. Tarriff, Chief Executive Officer, Independent Director
• Pete A. Meyers, Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
• David E. Riggs, Chief Financial Officer
• Steven L. Krill Ph.D., Executive Vice President, Chief Scientific Officer
• Adrian J. Hepner M.D. Ph.D, Executive Vice President, Chief Medical Officer
• Douglas L. Braunstein, Independent Director
• Richard A. Edlin, Independent Director
• Sander A. Flaum, Independent Director
• Robert L. Glenning, Independent Director

Eagle Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (12.07%), BlackRock Inc. (7.84%), Victory Capital Management Inc. (6.33%), Thrivent Financial For Lutherans (5.42%), State Street Corp (4.59%) and Iridian Asset Management LLC CT (4.54%). Company insiders that own Eagle Pharmaceuticals stock include David Pernock, Douglas L Braunstein, Michael Graves, Pete A Meyers, Proquest Investments Iv, LP, Proquest Management Llc, Richard A Edlin, Sander A Flaum, Sander A Flaum, Scott Tarriff, Steven B Ratoff and Steven L Krill. View Institutional Ownership Trends for Eagle Pharmaceuticals.

Eagle Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Iridian Asset Management LLC CT, Quantitative Investment Management LLC, C WorldWide Group Holding A S, First Eagle Investment Management LLC, OxFORD Asset Management LLP, BlackRock Inc. and Nationwide Fund Advisors. Company insiders that have sold Eagle Pharmaceuticals stock in the last year include Proquest Investments Iv, LP, Sander A Flaum, Steven B Ratoff and Steven L Krill. View Insider Buying and Selling for Eagle Pharmaceuticals.

Eagle Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Thrivent Financial For Lutherans, Lazard Asset Management LLC, State Street Corp, Old Mutual Global Investors UK Ltd., Vanguard Group Inc., Granite Investment Partners LLC and Rice Hall James & Associates LLC. Company insiders that have bought Eagle Pharmaceuticals stock in the last two years include David Pernock, Douglas L Braunstein, Michael Graves, Pete A Meyers and Richard A Edlin. View Insider Buying and Selling for Eagle Pharmaceuticals.

Shares of Eagle Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Eagle Pharmaceuticals stock can currently be purchased for approximately $56.02.